Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 Cancer vaccines – where are we? February 24, 2023 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 EMA Recommends Granting a Marketing Authorisation for Phesgo (Pertuzumab / Trastuzumab) November 19, 2020 Load more HOT NEWS Tips On Staying Cool During a Heat Wave Έγκριση νέας επικουρικής θεραπείας για τον θετικά πρώιμο καρκίνο του μαστού Honeybee Venom May Be the Next Treatment for Aggressive Breast Cancer Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România
